STOK · Stoke Therapeutics, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-18 | Kaye Edward M. MD |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
Common Stock
|
11,930 |
| 2026-08-18 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
Common Stock
|
4,525 |
| 2026-08-18 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
Common Stock
|
2,716 |
| 2026-08-18 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive. |
Common Stock
|
145 |
| 2026-08-18 | Kaye Edward M. MD |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive. |
Common Stock
|
637 |
| 2026-08-18 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive. |
Common Stock
|
242 |
| 2026-08-14 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Convert↑
|
Common Stock
|
10,000 |
| 2026-08-14 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Convert↓
Filing footnotes — Performance Stock Units (Direct)
Each performance stock unit represents a right to receive one share of the Issuer's common stock. Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. |
Performance Stock Units
|
6,000 |
| 2026-08-14 | Kaye Edward M. MD |
Director |
Convert↑
|
Common Stock
|
26,250 |
| 2026-08-14 | Kaye Edward M. MD |
Director |
Convert↓
Filing footnotes — Performance Stock Units (Direct)
Each performance stock unit represents a right to receive one share of the Issuer's common stock. Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. |
Performance Stock Units
|
26,250 |
| 2026-08-14 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Convert↑
|
Common Stock
|
6,000 |
| 2026-08-14 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Convert↓
Filing footnotes — Performance Stock Units (Direct)
Each performance stock unit represents a right to receive one share of the Issuer's common stock. Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. |
Performance Stock Units
|
10,000 |
| 2026-08-03 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $29.35 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
Common Stock
|
5,907 |
| 2026-08-03 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $29.54 per share, inclusive. |
Common Stock
|
1,269 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
Stock Option (Right to Buy)
(I)
|
21,000 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
Stock Option (Right to Buy)
(I)
|
14,777 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022. |
Stock Option (Right to Buy)
|
29,555 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
Stock Option (Right to Buy)
(I)
|
17,786 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021. |
Stock Option (Right to Buy)
|
14,777 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
Stock Option (Right to Buy)
(I)
|
11,650 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022. |
Stock Option (Right to Buy)
|
11,650 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
Stock Option (Right to Buy)
(I)
|
29,555 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
Stock Option (Right to Buy)
(I)
|
7,639 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date. |
Stock Option (Right to Buy)
|
17,786 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024. |
Stock Option (Right to Buy)
|
19,441 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025. |
Stock Option (Right to Buy)
|
7,639 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
Stock Option (Right to Buy)
(I)
|
29,747 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026. |
Stock Option (Right to Buy)
|
29,747 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023. |
Stock Option (Right to Buy)
|
21,000 |
| 2026-07-16 | Harrison Seth Loring |
Director |
Gift↑
Filing footnotes — Stock Option (Right to Buy) (Indirect)
The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
Stock Option (Right to Buy)
(I)
|
19,441 |
| 2026-07-15 | McCauley Thomas |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests as to 1/4 of the total award on July 15, 2027, and as to 1/48 of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. |
Stock Option (Right to Buy)
|
225,000 |
| 2026-07-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.37 per share, inclusive. |
Common Stock
|
500 |
| 2026-07-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $33.05 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
Common Stock
|
6,728 |
| 2026-06-16 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. |
Common Stock
|
1,457 |
| 2026-06-03 | Smith Julie |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | Burstein Jennifer |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | Kaye Edward M. MD |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | Krainer Adrian R. |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | Harrison Seth Loring |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | TZIANABOS ARTHUR |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | LEVIN ARTHUR A |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
1,795 |
| 2026-05-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
2,243 |
| 2026-04-03 | Kahn Clare |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option award shall vest as to 1/12 of the total award quarterly on the first calendar day of each July, October, January, and April, with the first tranche vesting on July 1, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. |
Stock Option (Right to Buy)
|
30,782 |
| 2026-04-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
1,838 |
| 2026-03-20 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.28 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
Common Stock
|
8,692 |
| 2026-03-20 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.34 to $35.12 per share, inclusive. |
Common Stock
|
601 |
| 2026-03-19 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
1,461 |
| 2026-03-19 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
1,365 |
| 2026-03-19 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. The option is fully vested and exercisable. |
Stock Option (Right to Buy)
|
1,365 |